FDA's new drug safety panel under fire

Senate Finance Committee Chairman Charles E. Grassley, R-Iowa, says the FDA's new drug safety panel is not an improvement on the current system and represents "nothing more than the status quo." Grassley's criticism was echoed by FDA whistle-blower David Graham, who said the panel is "severely biased in favor of industry." Congress and other administration officials are considering alternative proposals to address drug safety.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Chicago, IL
Senior Manager, Compliance
Fremont, CA
Manager, Business Conduct
Foster City, CA
Product Patent Attorney
Foster City, CA
Employment Counsel
Foster City, CA